Monotherapy with dextromethorphan or tirilazad - but not a combination of both - improves outcome after transient focal cerebral ischemia in rats

Experimental Brain Research

Volumn 122, Issue 1, 1998, Pages 121-127

  Schmid Elsaesser, Robert ^a   Zausinger, Stefan ^a   Hungerhuber, Edwin ^a   Baethmann, Alexander ^a   Reulen, Hanns Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cerebral blood flow; Cerebral ischemia; Combination drug therapy; Dextromethorphan; Neuroprotection; Rat; Tirilazad mesylate

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DEXTROMETHORPHAN; EXCITATORY AMINO ACID; FREE RADICAL; N METHYL DEXTRO ASPARTIC ACID; TIRILAZAD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; CELL DEATH; MALE; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RAT; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CEREBRAL INFARCTION; DEXTROMETHORPHAN; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; ISCHEMIC ATTACK, TRANSIENT; LASER-DOPPLER FLOWMETRY; MALE; NEUROPROTECTIVE AGENTS; PREGNATRIENES; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0031664740     PISSN: 00144819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002210050498     Document Type: Article

References (69)

1. Albers GW, Saenz RE, Moses JAJ, Choi DW (1991) Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia. Stroke 22:1075-1077
2. Albers GW, Saenz R, Moses JAJ (1992) Tolerability of oral dextromethorphan in patients with a history of brain ischemia. Clin Neuropharmacol 15:509-514
3. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM (1995) Safety, tolerability, and pharmacokinetics of the N-methyl-D-asparate antagonist dextrorphan in patients with acute stroke. Stroke 26:254-258
4. Annels SJ, Ellis Y, Davies JA (1991) Non-opioid antitussives inhibit endogenous glutamate release from rabbit hippocampal slices. Brain Res 564:341-343
5. Barth A, Barth L, Newell DW (1996) Combination therapy with MK-801 and alpha-phenyl-tert-butyl-nitrone enhances protection against ischemic neuronal damage in organotypic hippocampal slice cultures. Exp Neurol 141:330-336
6. Bern JL, Peck R (1992) Dextromethorphan. An overview of safety issues. Drug Saf 7:190-199
7. Blin O, Azulay JP, Denuelle C, Bille Turc F, Braguer D, Besse D, Branger E, Crevat A, Serratrice G, Pouget JY (1996) A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis. Clin Neuropharmacol 19:189-192
8. Braughler JM, Hall ED, Jacobsen EJ, McCall JM, Means ED (1989) The 21-aminosteroids: potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drugs Future 14:143-152
9. Britton P, Lu XCM, Laskosky MS, Tortella FC (1997) Dextromethorphon protects against cerebral injury following transient, but not permanent, focal ischemia in rats. Life Sci 60:1729-1740
10. Carpenter CL, Marks SS, Watson DL, Greenberg DA (1988) Dextromethorphan and dextrorphan as calcium channel antagonists. Brain Res 439:372-375
11. Choi DW (1987) Dextrophan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res 403:333-336
12. Choi DW, Peters S, Viseskul V (1987) Dextrorphan and levorphanol selectively block N-methyl-D-aspartate receptor-mediated neurotoxicity on cortical neurons. J Pharmacol Exp Ther 242: 713-720
13. Cox JW, Sage GP, Wynalda MA, Ulrich RG, Larson PG, Su CC (1991) Plasma compatibility of injectables: comparison of intravenous U-74006F, a 21-aminosteroid antioxidant, with Dilantin brand of parenteral phenytoin. J Pharm Sci 80:371-375
14. Decoster MA, Klette KL, Knight ES, Tortella FC (1995) Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res 671:45-53
15. Du C, Hu R, Csernansky CA, Liu XZ, Hsu CY, Choi DW (1996a) Additive neuroprotective effects of dextrorphan and cycloheximide in rats subjected to transient focal cerebral ischemia. Brain Res 718:233-236
16. Du C, Hu R, Hsu CY, Choi DW (1996b) Dextrorphan reduces infarct volume, vascular injury, and brain edema after ischemic brain injury. J Neurotrauma 13:215-222
17. Fleishaker JC, Peters GR, Cathcart KS, Steenwyk RC (1993) Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger. II. Multiple-dose administration. J Clin Pharmacol 33:182-190
18. Fleishaker JC, Hulst LK, Peters GR (1994) The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. Clin Pharmacol Ther 56:389-397
19. Fletcher EJ, Church J, Abdelhamid K, Macdonald JF (1995) Blockade by sigma site ligands of N-methyl-D-aspartate-evoked responses in rat and mouse cultured hippocampal pyramidal neurones. Br J Pharmacol 116:2791-2800
20. Foutz AS, Pierrefiche O, Denavit Saubie M (1994) Combined blockade of NMDA and non-NMDA receptors produces respiratory arrest in the adult cat. Neuroreport 5:481-484
21. Goldberg MP, Pham PC, Choi DW (1987) Dextrorphan and dextromethorphan attenuate hypoxic injury in neuronal culture. Neurosci Lett 80:11-15
22. Haley EC Jr, Kassell NF, Apperson-Hansen C, Maile MH, Alves WM (1997) A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg 86:467-474
23. Hall ED (1995) Inhibition of lipid peroxidation in central nervous system trauma and ischemia. J Neurol Sci [Suppl] 134:79-83
24. Hall ED, Yonkers PA (1988) Attenuation of postischemic cerebral hypoperfusion by the 21-aminosteroid U74006F. Stroke 19:340-344
25. Hall ED, Pazara KE, Braughler JM (1991) Effects of tirilazad mesylate on postischemic brain lipid peroxidation and recovery of extracellular calcium in gerbils. Stroke 22:361-366
26. Haraldseth O, Gronas T, Unsgard G (1991) Quicker metabolic recovery after forebrain ischemia in rats treated with the antioxidant U74006F. Stroke 22:1188-1192
27. Karlsson BR, Loberg EM, Grogaard B, Steen PA (1992) The antioxidant tirilazad does not affect cerebral bloos flow or histopathologic changes following severe ischemia in rats. Acta Neurol Scand 90:256-262
28. Kassell NF, Haley EC, Apperson-Hansen C, Stat M, Alves WM, Dorsch NW, Fabinyi G, Matheson J, Reilly P, Siu K, Stokes B, Stuart G, Koos W, Calliauw L, Selosse P, Astrup J, Gjerris F, Mendelow AD, Castel JP, Christiaens JL, Cophignon J, Keravel Y, Lagarrigue J, Mourier K, Philippon J, Brandt L, Vonessen C, Persson L, Brock M, Fahlbusch P, Gilsbach J, Hassler W, Perneczky A, Samii M, Schmiedek P, Mee E, Arista A, Cantore G, Carteri A, Collice M, Dapian R, Marini G, Menonna P, Baena RRY, Matteo PS, Testa PC, Villani R, Antunes JL (1996) Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg 84:221-228
29. Klette KL, Decoster MA, Moreton JE, Tortella FC (1995) Role of calcium in sigma-mediated neuroprotection in rat primary cortical neurons. Brain Res 704:31-41
30. Koizumi J, Yoshida Y, Nakazawa T, Ooneda G (1986) Experimental studies of ischemic brain edema. 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke 8:1-8
31. Lo EH, Steinberg GK (1991) Effects of dextromethorphan on regional cerebral blood flow in focal cerebral ischemia. J Cereb Blood Flow Metab 11:803-809
32. Löscher W, Wlaz P, Szabo L (1998) Focal ischemia enhances the adverse effect potential of N-methyl-D-aspartate receptor antagonists in rats. Neurosci Lett 240:33-36
33. Marshall LF, Marshall SB (1995) Pitfalls and advances from the international tirilazad trial in moderate and severe head injury. J Neurotrauma 12:929-932
34. Maruki Y, Koehler RC, Kirsch JR, Blizzard KK, Traystman RJ (1995) Tirilazad pretreatment improves early cerebral metabolic and blood flow recovery from hyperglycemia ischemia. J Cereb Blood Flow Metab 15:88-96
35. Means ED (1994) 21-aminosteroids ("lazaroids"). Adv Exp Med Biol 366:307-312
36. Meldrum BS (1995) Cytoprotective therapies in stroke. Curr Opin Neurol 8:15-23
37. Mori E, Ember J, Copeland BR, Thomas WS, del Zoppo GJ (1995) Effect of tirilazad mesylate on middle cerebral artery occlusion/ reperfusion in nonhuman primates. Cerebrovasc Dis 5:342-349
38. Muir KW, Lees KR (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke 26:503-513
39. Musacchio JM, Klein M, Canoll PD (1989) Dextromethorphan and sigma ligands: common sites but diverse effects. Life Sci 45:1721-1732
40. Müller TB, Haraldseth O, Jones RA, Sebastiani G, Lindboe CF, Unsgard G, Oksendal AN (1995) Perfusion and diffusion-weighted MR imaging for in vivo evaluation of treatment with U74389G in a rat stroke model. Stroke 26:1453-1458
41. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA (1991) NMDA antagonist neurotoxicity: mechanism and prevention. Science 254:1515-1518
42. Pellegrino LJ (1979) A stereotaxic atlas of the rat brain. Plenum Press, New York
43. Rothman SM, Olney JW (1986) Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 19:105-111
44. Rothman SM, Olney JW (1995) Excitotoxicity and the NMDA receptor - still lethal after eight years. Trends Neurosci 18:57-58
45. Sato PH, Hall ED (1992) Tirilazad mesylate protects vitamin-C and vitamin-E in brain ischemia-reperfusion injury. J Neurochem 58:2263-2268
46. Schmid-Elsaesser R, Zausinger S, Baethmann A, Reulen HJ (1996) Subarachnoid hemorrhage in an experimental model of focal cerebral ischemia (abstract). Int J Microcirc Clin Exp 16 [Suppl]:225
47. Schmid-Elsaesser R, Zausinger S, Hungerhuber E, Baethmann A, Reulen HJ (1997) Additive neuroprotective effects of magnesium and tirilazad in rats subjected to transient focal cerebral ischemia (abstract). J Cereb Blood Flow Metab 17[Suppl 1]:S103
48. Schmitt B, Netzer R, Fanconi S, Baumann P, Boltshauser E (1994) Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients. J Neurol Neurosurg Psychiatry 57:333-339
49. Siesjö BK (1992) Pathophysiology and treatment of focal cerebral ischemia. Part I: pathophysiology. J Neurosurg 77:169-184
50. Sills MA, Loo PS (1989) Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate. Mol Pharmacol 36:160-165
51. Sinclair JG, Lo GF (1977) The blockade of serotonin uptake into synaptosomes: relationship to an interaction with monoamine oxidase inhibitors. Can J Physiol Pharmacol 55:180-187
52. Steinberg GK, George CP, DeLAPaz R, Shibata DK, Gross T (1988a) Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits. Stroke 19:1112-1118
53. Steinberg GK, Saleh J, Kunis D (1988b) Delayed treatment with dextromethorphan and dextrorphan reduces cerebral damage after transient focal ischemia. Neurosci Lett 89:193-197
54. Steinberg GK, Lo EH, Kunis DM, Grant GA, Poljak A, DeLaPaz R (1991) Dextromethorphan alters cerebral blood flow and protects against cerebral injury following focal ischemia. Neurosci Lett 133:225-228
55. Steinberg GK, Kunis D, DeLaPaz R, Poljak A (1993) Neuroprotection following focal cerebral ischaemia with the NMDA antagonist dextromethorphan has a favourable dose response profile. Neurol Res 15:174-180
56. Steinberg GK, Yoon EJ, Kunis DM, Sun GH, Maier CM, Grant GA (1995) Neuroprotection by N-methyl-D-aspartate antagonists in focal cerebral ischemia is dependent on continued maintenance dosing. Neuroscience 64:99-107
57. Steinberg GK, Bell TE, Yenari MA (1996) Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. J Neurosurg 84:860-866
58. Taylor BM, Fleming WE, Benjamin CW, Wu YK, Mthews WR, Sun FF (1996) The mechanism of cytoprotective action of lazaroids inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion. J Pharmacol Exp Ther 276:1224-1231
59. The RANTTAS Investigators (1996) A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 27:1453-1458
60. The STIPAS Investigators (1994) Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 25:418-423
61. Tortella FC, Ferkany JW, Pontecorvo MJ (1988) Anticonvulsant effects of dextrorphan in rats: possible involvement in dextromethorphan-induced seizure protection. Life Sci 42:2509-2514
62. Tortella FC, Martin DA, Allot CP, Steel JA, Blackburn TP, Loveday BE, Russel NJ (1989) Dextromethorphan attnuates post-ischemic hypoperfusion following incomplete globalischemia in the anesthetized rat. Brain Res 482:179-183
63. Tortella FC, Klette KL, Decoster MA, Davies BJ, Newman AH (1995) Dextromethorphan analogs are neuroprotective in vitro and block glutamate-induced excitotoxic calcium signals in neurons. Neurosci Lett 198:79-82
64. Trube G, Netzer R (1994) Dextromethorphan: cellular effects reducing neuronal hyperactivity. Epilepsia 35:S62-S67
65. Villa RF, Gorini A (1997) Pharmacology of lazaroids and brain energy metabolism: a review. Pharmacol Rev 49:99-136
66. Wong BY, Boulter DA, Choi DW, Prince DA (1988) Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices. Neurosci Lett 85:261-266
67. Woodworth JR, Dennis SR, Moore L, Rotenberg KS (1987) The polymorphic metabolism of destromethorphan. J Clin Pharmacol 27:139-143
68. Xue D, Slivka A, Buchan AM (1992) Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Stroke 23:894-899
69. Zhao Q, Memezawa H, Smith ML, Siesjö BK (1994) Hyperthermia complicates middle cerebral artery occlusion induced by an intraluminal filament. Brain Res 649:253-259